Merck buys VC-backed Chord Therapeutics

Merck has acquired Chord Therapeutics, a developer of drugs for rare neuroinflammatory diseases.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this